CSBR logo

CHAMPIONS ONCOLOGY INC

CSBRNASDAQ
πŸ† #4147 by market capEarnings Dec 14US Equity
$4.75β–² $0.06 (+1.28%)
Latest quote
πŸ””
Track CSBR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.3%
7dβ–² 0.0%
14dβ–Ό 3.6%
30dβ–Ό 3.9%
ytdβ–Ό 35.3%
1yβ–Ό 30.4%
🏦Market Cap
$66M
Small Cap
πŸ“ˆRevenue Growth (YoY)
6.7%
Slowing
πŸ“ŠGross Margin
49.8%
Healthy
πŸ’΅FCF Margin
12.6%
Healthy
βš–οΈP/S Ratio
1.1x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$4.75 – $4.75
52-Week Range
$4.59 – $8.31
Volume (shares)
100
Avg Volume (shares)
β€”
Shares Outstanding
13.9M
Next Earnings
2026-12-14

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
1.1x
EPS (TTM)
$-0.08
Dividend Yield
β€”
Dilution (1yr)
βˆ’3.9%
CSBR logo

CHAMPIONS ONCOLOGY INC

CSBR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$59Mβ–² +4.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
48.0%β–Ό βˆ’4.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$1Mβ–Ό βˆ’123.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–Ό βˆ’172.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
13.9Mβ–Ό βˆ’3.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$7Mβ–Ό βˆ’$10M YoY
StockOtter Β· stockotter.space

About CHAMPIONS ONCOLOGY INC

Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.